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Products of the steroid receptor RNA activator (SRA1) gene have the unusual property to function
both at the RNA and the protein levels. SRA-RNA has long been known to increase the activity of
multiple nuclear receptors. It has more recently been proposed than steroid receptor RNA activator
protein (SRAP) also modulates steroid receptors activity. Herein, we show for the ﬁrst time that
SRAP physically interacts with multiple transcription factors and is recruited to speciﬁc promoter
regions. Artiﬁcially recruiting SRAP to the promoter of a luciferase reporter gene under the control
of the strong transcriptional activator VP16 leads to a decrease in transcription. Altogether we pro-
pose that SRAP could be a new transcriptional regulator, able to function as a repressor through
direct association with promoters.
Structured summary:
MINT-7761068: SRAP (uniprotkb:Q9HD15) physically interacts (MI:0915) with HDAC2 (uni-
protkb:Q92769) by anti bait coimmunoprecipitation (MI:0006)
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction and the retinoic acid (RAR) receptors) and the myogenic differenti-The steroid receptor RNA activator (SRA) has originally been
characterized as a non-coding transcript speciﬁcally co-activating
steroid receptors [23,25]. This transcript acts embedded in ribonu-
cleo-protein complexes containing steroid receptors as well as
other proteins, such as the RNA helicase p68 or the SRA stem-loop
interacting RNA binding protein (SLIRP), physically interacting
with SRA and acting either as positive or negative functional regu-
lators [2,9,25]. Secondary sub-structures (STRs) located within SRA
core sequence (exons 2–5) are critical for these physical interac-
tions to occur and therefore directly contribute to the co-activator
role of this messenger [24]. It has now been demonstrated that
SRA-RNA regulates the activity of additional transcription factors,
including other nuclear receptors (such as the vitamin D (VDR)chemical Societies. Published by E
; SRAP, steroid receptor RNA
ichostatin A
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ue).ation factor MyoD [25]. This functional transcript therefore appears
to have a much broader role than originally anticipated, participat-
ing in multiple normal and pathological events including tissue dif-
ferentiation and tumorigenesis [2,9,25].
Coding SRA-RNAs, differing from the originally described non-
coding RNA by an extended exon-1, have now been characterized
[5,11,25]. Thisadditional sequencecontains twomethionine codons,
respectively, initiating a 236 and a 224 amino-acids long open read-
ing frameterminated inexon-5. Thecorrespondingendogenouspro-
teins steroid receptor RNA activator proteins (SRAPs), that has been
detected inmultiple tissues andcell lines [6,22,34], contain twophy-
logenetically conserved domains (amino-acids 15–52 and amino-
acids 135–204 [25]). This strong conservation suggests that bothdo-
mains contribute to SRAP potential functions.
Most studies only focused on SRA-RNA and little is known about
SRAP putative functions. It has nonetheless been proposed that
SRAP, as its RNA counterpart, might also modulate the activity of
steroid receptors [1,7,20,22]. SRAP was indeed found to physically
interact with the androgen receptor and to enhance its ligand-in-
duced transcriptional activity in prostate cells [20,22]. Transientlsevier B.V. All rights reserved.
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that SRAP could also enhance the transcriptional activities of estro-
gen (ESR1), glucocorticoid (GR) and peroxisome proliferator-acti-
vated receptor gamma (PPARc) receptors [7,20,22]. Altogether,
SRAP is currently suspected to act as positive regulator of several
nuclear receptors.
The potential involvement of SRAP in mechanisms underlying
transcriptional regulation is further substantiated by the identity
of proteins characterized as co-immunoprecipitating with SRAP
in Hela cells [19,25,28]. Known transcriptional regulators, such as
SMARCC2 (member of the SWI/SNF chromatin remodeling com-
plex, [35]) or the RNA helicase p68 [16], have indeed been identi-
ﬁed as forming complexes with SRAP [19,28]. Most interestingly,
the identiﬁcation of the myocyte enhancer factor 2A (MEF2A) as
one of SRAP protein partners further suggested that, beside andro-
gen receptor, SRAP might also physically interact with other tran-
scription factors. This would imply that SRAP, as its RNA, might
modulate the transcriptional activity of a much wider range of
transcription factors than initially predicted. Herein, we ﬁrst used
protein array to investigate SRAP potential interactions with multi-
ple transcription factors and Chromatin immunoprecipitation
(ChIP) to identify promoter regions potentially recruiting SRAP.
We further assessed the potential effect of recruiting SRAP to the
promoter region of an actively transcribed reporter gene.
2. Materials and methods
2.1. Plasmids
CMV-Renilla-luciferase, LexA-VP16, and L8G5-luciferase plas-
mids were previously described [3,6,17]. SDM1 and SDM7 muta-
tions, impairing SRA-RNA action [24], were introduced in SRAP
coding sequence using the QuickChange Site-Directed Mutagenesis
Kit (Stratagene) to generate SRAP-SDM as described [7]. GAL4-
SRAP-SDM, GAL4-SRAP-N and GAL4-SRAP-C were obtained by,
respectively, cloning full-length SRAP-SDM, aa 1–100, and aa
101–236 in frame with an existing GAL4 coding plasmid as de-
scribed for the Receptor-Interacting Protein 140 [3].
2.2. Reporter assays
LexA-VP16 Luciferase reporter assays were performed using
Hela cells as previously described [3,17]. Brieﬂy, Hela cells were
co-transfected with 0.1 lg of L8G5-luciferase, 0.05 lg LexA-VP16,
0.025 lg Renilla luciferase and 0.1 lg of GAL4, GAL4-SRAP-SDM,
GAL4-SRAP-SDM-N, or GAL4-SRAP-SDM-C. Trichostatin A (TSA,
Sigma, St. Louis, MO) was added to the indicated concentrations
16 h before lysis. Cells were harvested 24 h after transfection and
Renilla luciferase and luciferase activities assessed and analyzed
as previously described [3,17]. Following normalization to Renilla
luciferase (accounting for transfection efﬁciencies), relative lucifer-
ase activity (RLU) of cells transfected with GAL4 alone with LexA-
VP16 was arbitrarily assigned as 1. Luciferase activities within cells
transfected with other vectors were expressed relatively. Results
represent the average of at least three independent experiments
performed in triplicate. Standard deviations were calculated and
differences between results obtained with the various constructs
and control (GAL4) were tested using the Student’s t-test (two-
tailed distribution, two-sample equal variance).
2.3. Immunoprecipitation and histone de-acetylase (HDAC) activity
assay
Human breast cancer cell lines expressing SRAP-V5-tagged
(MCF-7-SRAP-V5-High.A) and control MCF-7-SE cells were cul-
tured as previously described [6]. Nuclear proteins were isolated(Panomics, Redwood City, CA) and incubated with agarose-beads-
anti-V5 antibodies (Sigma, St. Louis, MO) according to the manu-
facturer’s instructions to immunoprecipitate SRAP-V5 containing
complexes. As an additional control, MCF-7-SRAP-V5-High.A ex-
tract was immunoprecipitated in the presence of V5 peptide (350
excess binding capacity of beads). HDAC activities were assayed
using the ﬂuorometric HDAC assay kit (Abcam, Cambridge, MA)
as indicated by the manufacturer. For each experiment (n = 4)
and each cell type, the immunoprecipitated HDAC activity was ex-
pressed as a percentage of the value before immunoprecipitation
and normalized to the average residual background signal obtained
with MCF-7-SE cells. Results correspond to the average immuno-
precipitated HDAC activity expressed as percentage of total activ-
ity. Signiﬁcant differences (P < 0.05) between samples were
assessed using the Student’s t-test (two-tailed distribution, paired).
Nuclear extracts from MCF-7 breast cancer cells were prepared
and endogenous SRAP immunoprecipitated using a rabbit poly-
clonal anti-SRAP antibody (#A300-743A, Bethyl Laboratories Inc.,
Montgomery, TX) as described [11,33]. Irrelevant isotype matched
antibodies (rabbit anti-goat IgGs, Jackson Immunoresearch Lab-
Inc., West Grove, PA) were used as non-speciﬁc control. Presence
of HDAC-2 in co-immunoprecipitated lysate was assessed by Wes-
tern blot (Cell Signaling Technology Inc., Boston, MA) as previously
reported [11,33].
2.4. Transcription factor protein array
Transcription factors protein-array analysis (TF-array,
Panomics, Redwood City, CA) was performed as per manufacturers’
instructions. Brieﬂy, TF-array-I was incubated with 5 lg of recom-
binant SRAP protein (ProMab Biotechnologies Inc., Albany, CA) or
without (control blot) for 2 h at room temperature. Immunodetec-
tion was performed using a primary anti-SRAP antibody (targeting
aa 20–34) and chemiluminescence signals were captured and ana-
lyzed as described [6]. For both control and samples blots, intensity
of the area (in counts/mm2) encompassing the two spots corre-
sponding to each transcription factor was ﬁrst corrected by sub-
tracting the signal of an immediately negative adjacent area
(local background). For each transcription factor, the relative inter-
action (RI) was then determined by subtracting signal-control from
signal-sample. Interactions were arbitrarily classiﬁed as strong
(+++, RI > 15 000 counts/mm2), positive (++, 1000 < RI < 10 000 -
counts/mm2), intermediate (+, 400 < RI < 1000 counts/mm2) and
weak/negative (RI < 400 counts/mm2).
2.5. Isolation of DNA-associated proteins by formaldehyde
cross-linking
DNA-associated proteins from MCF-7-SRAP-V5-High.A cells
were isolated as previously described [31]. As a control for non-
speciﬁc precipitation by hydroxy-apatite, not cross-linked cells ex-
tracts were used. Proteins precipitated with hydroxy-apatite were
detected by Western blot using Anti-SRAP antibodies, anti-SP3 and
anti-GAPDH antibody as described [6].
2.6. Chromatin immunoprecipitation assays and analysis
Chromatin immunoprecipitation assays were conducted as de-
scribed [33]. Brieﬂy, MCF-7 cells stably expressing SRAP-V5 cells
were cultured in complete DMEM supplemented with 5% FBS. Cells
were treated with formaldehyde in order to cross-link protein to
DNA. Cells were then lysed and nuclear extracts were sonicated.
The supernatants were then incubated overnight with a mouse
anti-V5 antibody (Invitrogen) or the V5 antibody pre-incubated
with the V5 peptide (negative control) (In a 100-fold excess).
The immuno-complexes were collected by addition of protein
Table 1
Transcription factors analyzed for their direct physical interaction with SRAP.
Transcription factor description Relative
interactiona
AES Amino-terminal enhancer of split 61 
AP2A Transcription factor AP-2 alpha 2346 ++
ASH2L Ash2 (absent, small, or homeotic)-like 316 
ATF1 Activating transcription factor 1 810 +
ATF2 Activating transcription factor 2 996 +
ATF3 Activating transcription factor 3 595 +
ATF4 Activating transcription factor 4 1158 ++
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teinase K. DNA fragments were puriﬁed with a QIAquick Spin Kit
(Qiagen, CA) and ampliﬁed by using the WGA ampliﬁcation kit
(Sigma, St. Louis, MO) according to the manufacturers protocol.
The precipitated samples were sent to Nimblegen for Chromatin
immunoprecipitation on CHIP (ChIP on CHIP) analysis using the
human ChIP 385K Refseq promoter array (Nimblegen). Promoter
regions that were enriched by at least 4-folds (peak score >2) in
the SRAP-V5 precipitated sample compared to the negative control
were further analyzed. Using the Genomatix RegionMiner software
(Ann Arbor, MI), we determined the frequency of transcription fac-
tor binding sites and their over-representation against an average
corresponding to the population of all annotated promoter regions.
Obtained Z-score corresponds to the distance from the promoter
population mean in units of the population standard deviation.
3. Results and discussion
3.1. SRAP interacts with multiple transcription factors
The fact that SRAP was found to directly interact with the
androgen receptor [20] and form complexes with another known
transcription factor MEF2A [19,28], led us to investigate whether
it could also interact with other transcription factors. Using protein
array (Fig. 1), we found that 29 out of 48 different transcription fac-
tors tested directly interacted with recombinant SRAP. The
strength of these interactions varies upon the transcription factor
considered. As such, SRAP appears to more strongly interact with
ESR2 than with ESR1 (Table 1). This raises the interesting conceptFig. 1. SRAP directly interacts with transcription factors in vitro. A protein array
containing 48 transcription factors spotted in duplicate was incubated with human
recombinant SRAP (SRAP) or no protein (control) before immunodetection with
anti-SRAP antibodies as outlined in Section 2. Following signal analysis, interactions
with SRAP were qualiﬁed as high (+++, light blue box), positive (++, dark blue box),
intermediate (+, green box) or weak/negative (, red box). Relative interactions are
detailed in Table 1.that in speciﬁc contexts, the relative amount of estrogen receptor
beta might interfere with the formation of complexes between
SRAP and estrogen receptor alpha. This possibility might become
of particular interest when considering the differential expression
and roles played by these two receptors in breast tumorigenesis
and tumor progression [8,30]. The observation that SRAP directly
interacts with estrogen and glucocorticoid receptors ﬁts with pre-
vious data from Kawashima et al. showing a direct interaction be-
tween SRAP and androgen receptor. This suggests that SRAP has
the ability to modulate the action of steroid receptors (ESR1, AR
and GR) likely through direct interactions.
Beside steroid receptors, several other transcription factors such
as FOS [27], GATA1 [32] and ETS1 [10], known to participate in crit-
ical normal developmental steps or to events underlying tumori-
genesis, directly interact with SRAP (Table 1). It is of interest that
an interaction has been observed between SRAP and HAND1,
essential to heart development [13]. Indeed, a recent study hasBLZF1 Basic leucine zipper nuclear factor 1 965 +
BTG2 B-cell translocation gene 2 465 +
C/EBPa CCAAT/enhancer binding protein alpha 739 +
CART1 Cartilage paired-class homeoprotein 840 +
CBFB CBFB: core-binding factor, beta subunit 0 
CDX2 CDX2: caudal type homeo box transcription factor 2 0 
CERM cAMP responsive element modulator 146 
CREB1 cAMP responsive element binding protein 1 1051 ++
CREBL2 cAMP responsive element binding protein-like 0 
CRSP9 Cofactor-required for Sp1 transcriptional activation,
subunit 9
0 
DDIT3 DNA-damage-inducible transcript 3 2594 ++
DLX4 Distal-less homeobox 4 172 
DMTF1 Cyclin D binding myb-like transcription factor 2663 ++
DR1 Down-regulator of transcription 1, TBP-binding 326 
E2F3 E2F transcription factor 3 3286 ++
E2F4 E2F transcription factor 4 0 
E2F5 E2F transcription factor 5 0 
E2F6 E2F transcription factor 6 0 
EGR1 Early growth response 1 3373 ++
EGR2 Early growth response 2 913 +
EGR4 Early growth response 4 398 
ELK ELK1, member of ETS oncogene family 0 
ESR1 Estrogen-related receptor gamma 2805 ++
ESR2 Estrogen receptor alpha 25 289 +++
ERRg Estrogen receptor beta 1954 ++
ETS1 v-ets erythroblastosis virus E26 oncogene homolog 1 1607 ++
ETS2 v-ets erythroblastosis virus E26 oncogene homolog 2 435 +
F2RL1 Coagulation factor II (thrombin) receptor-like 1 0 
FOS v-fos FBJ murine osteosarcoma viral oncogene
homolog
1126 ++
FOSB FBJ murine osteosarcoma viral oncogene homolog B 1468 ++
FOSL1 FOS-like antigen 1 0 
FOSL2 FOS-like antigen 2 2097 ++
GATA1 GATA binding protein 1 2215 ++
GCNF Nuclear receptor subfamily 6, group A, member 1 125 
GMEB1 Glucocorticoid modulatory element binding protein 1 0 
GR Glucocorticoid receptor 735 +
GTF2B General transcription factor IIB 5478 ++
GTF2H2 General transcription factor IIH, polypeptide 2 578 +
GTF2I General transcription factor II, I 0 
GTF3C5 General transcription factor IIIC, polypeptide 5 1195 ++
HAND1 Heart and neural crest derivatives expressed 1 16 784 +++
a High (+++), positive (++), intermediate (+) and weak/negative () interaction.
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dysfunction in zebraﬁsh, linking for the ﬁrst time SRA and heart
diseases [15]. The wide range of transcription factors identiﬁed
as interacting with SRAP suggests that many normal and patho-
genic events might involve this newly described protein.
In normal conditions, most transcription factors and nuclear
receptors are localized and exert their functions in the nucleus.
In breast cancer cells, SRAP, which contains a nuclear localization
signal, is detected both in the cytoplasm and the nucleus
[11,25,34]. The potential for this protein to localize in the nucleus,
further demonstrated by the identiﬁcation of SRAP and many of its
co-immunoprecipitated partners in nuclear extracts from Hela
cells [19,28], implies a potential role in this cellular compartment.
Altogether, this led us to investigate the possibility of a recruit-
ment of SRAP directly on chromatin.
3.2. SRAP is associated with chromatin
We used a previously described assay consisting in cross-link-
ing DNA and associated proteins, precipitating DNA, and analyzing
co-precipitated proteins using Western blot [31]. We found that
both exogenous tagged and endogenous SRAP precipitated with
DNA in cells stably expressing SRAP-V5 tagged protein (MCF-7-
SRAP-V5-High.A cells [6], Supplementary material, Fig. S1). As
anticipated, both long (SP3L) and short (SP3M) transcription factor
SP3 isoforms, known to be associated with DNA, were also de-Table 2
Partial list of transcription factor (TF) binding sites families found in 2319 sequences iden
Family of TF Number of sequences Number of matches Z-Scorea Tra
V$NR2F 1652 3300 11.33 Nuc
V$GREF 1057 1856 9 Glu
V$PERO 920 1218 8.39 Per
V$SRFF 886 1583 8.34 Ser
V$STAT 1265 2843 7.13 Sig
V$CAAT 1163 1766 6.89 CCA
V$AIRE 358 408 6.87 Aut
V$RBPF 688 869 6.76 RBP
V$IKRS 838 1107 6.72 Ika
V$HAML 648 792 6.62 Hu
V$GATA 1401 2608 6.51 GA
V$EREF 685 936 6.38 Estr
V$MOKF 879 1147 6.24 Mo
V$TALE 840 1140 5.98 TAL
V$PRDF 753 994 5.54 Pos
V$ZFTR 561 683 5.4 Zin
V$YY1F 1109 1618 5.34 Act
V$SORY 1629 3905 5.33 SOX
V$SF1F 565 683 5.22 Ver
V$NBRE 394 437 5.19 NG
V$RXRF 1640 3386 5.13 RXR
V$LEFF 801 1043 5.12 LEF
V$BTBF 307 320 5.06 BTB
V$RP58 324 371 5.06 RP5
V$CLOX 1099 2055 5.02 CLO
V$EVI1 1455 3101 4.98 EVI
V$TEAF 645 761 4.94 TEA
V$HEAT 1142 1937 4.79 Hea
V$BCDF 953 1510 4.67 Bic
V$HAND 1433 2861 4.64 Tw
V$HMTB 610 763 4.6 Hu
V$HOXH 750 1009 4.6 HO
V$NEUR 891 1223 4.46 Neu
V$SIXF 543 663 4.39 Sin
V$SMAD 610 777 4.34 Ver
V$PBXC 721 936 4.34 PBX
V$GCMF 601 763 4.32 Cho
V$AP1F 548 872 4.31 AP1
V$PAX8 598 728 4.3 PAX
O$INRE 636 794 4.29 Cor
a Distance from the population mean in units of the population standard deviation.tected in the DNA bound protein fraction. None of these associa-
tions were observed in the absence of cross-linking. On the other
hand, the mainly cytoplasmic protein glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was present in the protein lysate but not
associated with DNA. The fact that SRAP could indeed be associated
with chromatin led us to investigate further whether SRAP might
be associated to speciﬁc promoter regions.
3.3. SRAP binds to promoter regions enriched in nuclear receptor
binding sites
To identify promoter regions potentially recruiting SRAP, we
performed Chromatin immunoprecipitation (ChIP)-CHIP arrays.
Breast cancer cells stably expressing SRAP-V5 tagged protein [6]
were treated, DNA precipitated with anti-V5 antibody, and recog-
nized promoter regions identiﬁed as described in Section 2. As a
negative control, we used a V5 antibody pre-incubated with 100-
fold excess V5 peptide. We were able to identify 2319 regions that
were enriched at least by four folds in the SRAP-V5 chromatin
immunoprecipitated samples as compared to the negative control
(Supplementary material, S2). The transcription factor binding
sites present within these sequences have been sorted according
to their over-representation coefﬁcient (Z-score). A list of the name
of transcription factor families corresponding to the 40 most over-
represented binding sites out of the 176 present is shown Table 2.
Binding sites for nuclear receptors (in italics) are highly enriched intiﬁed following ChIP-CHIP array.
nscription factor families full name Rank/176
lear receptor subfamily 2 factors 1
cocorticoid responsive and related factors 2
oxisome proliferator-activated receptor 3
um response element binding factor 4
nal transducer and activator of transcription 5
AT binding factors 6
oimmune regulatory element binding factors 7
J – kappa 8
ros zinc ﬁnger family 9
man acute myelogenous leukemia factors 10
TA binding factors 11
ogen response elements 12
use Krueppel like factor 13
E homeodomain class recognizing TG motifs 14
itive regulatory domain I binding factor 15
c ﬁnger transcriptional repressor 16
ivator/repressor binding to transcription initiation site 17
/SRY-sex/testis determining and related HMG box factors 18
tebrate steroidogenic factor 19
FI-B response elements, nur subfamily of nuclear receptors 20
heterodimer binding sites 21
1/TCF 22
/POZ transcription factor 23
8 (ZFP238) zinc ﬁnger protein 24
X and CLOX homology (CDP) factors 25
1-myleoid transforming protein 26
/ATTS DNA binding domain factors 27
t shock factors 28
oid-like homeodomain transcription factors 29
ist subfamily of class B bHLH transcription factors 30
man muscle-speciﬁc Mt binding site 31
X – MEIS1 heterodimers 32
roD, Beta2, HLH domain 33
e oculis (SIX) homeodomain factors 34
tebrate SMAD family of transcription factors 35
1 – MEIS1 complexes 36
rion-speciﬁc transcription factors with a GCM DNA bind. domain 37
, Activating protein 1 38
-2/5/8 binding sites 39
e promoter initiator elements 40
2222 S. Chooniedass-Kothari et al. / FEBS Letters 584 (2010) 2218–2224promoter sequences precipitating with SRAP. These include nucle-
ar receptor subfamily two factors binding element, as well gluco-
corticoid responsive, peroxisome proliferator-activator receptor
and estrogen receptor responsive elements. These results suggest
that previously seen physical interactions between nuclear recep-
tors such as GR or ESRs and SRAP might result in the targeting of
this later protein to speciﬁc promoter regions. Interestingly, bind-
ing sites for GATA, HAND and AP1 (recognized by FOS) are also en-
riched (Table 2 in bold). This in turn strongly suggests that SRAP
might also be recruited to particular promoter regions through
physical interaction with transcription factors such as GATA1,
HAND1 or FOS. This is the ﬁrst time SRAP is found recruited at pro-
moter levels. The overall effect of recruiting SRAP on a given pro-
moter region is likely to be speciﬁc of the exact region involved,
the existing genomic context, the gene considered, as well as the
presence or absence of other factors. Individual studies are there-
fore obviously needed to decipher the exact role SRAP might have
on the transcription of genes controlled by promoters it is locatedFig. 2. SRAP and its two conserved domains repress transcription when physically recrui
Hela cells were co-transfected with L8G5-luciferase together with GAL-4, GAL4-SRAP-
luciferase activity assessed as described in Section 2. Bars and stars represent standard
control, respectively.on. It was however of interest to investigate whether forcing the
recruitment of SRAP on a given promoter might result in any tran-
scriptional modiﬁcation.
3.4. SRAP has a transcriptional repressive activity sensitive to TSA
In order to determine the generic effect of recruiting SRAP at a
given promoter, we used an artiﬁcial luciferase reporter system to
recruit the hybrid GAL4-SRAP protein in close proximity to the
LEXA-VP16 transcriptional activator on the promoter of the
GAL4-LEXA-luciferase reporter vector. To exclude any potential
inﬂuence of SRA-RNA in the effect observed, we used a construct
(GAL4-SRAP-SDM), which contains silent mutations (SDM1 and
SDM7) shown to alter sub-structures STR1 and 7 and interfere with
SRA-RNA co-activation function [24]. We ﬁrst analyzed the ability
of full-length SRAP-SDM to modulate the activity of LexA-VP16
when physically recruited on adjacent promoter sequences
(Fig. 2A and B). We found that GAL4-SRAP-SDM decreased theted at the promoter level. (A) Schematic of LexA-VP16 assay. (B) Constructs used. (C)
SDM, GAL4-SRAP-N or GAL4-SRAP-C, treated with increasing amount of TSA and
deviations (n = 4) and signiﬁcant (Student’s t-test, P < 0.05) difference with GAL4
S. Chooniedass-Kothari et al. / FEBS Letters 584 (2010) 2218–2224 2223activity of VP16 in this system (Fig. 2C). It should be noted that a
construct encoding for SRAP-SDM but exempt of GAL4-DBD (there-
fore not physically recruited to the promoter) did not have any ef-
fects in this system (data not shown). As outlined earlier, SRAP
contains two N- and C-terminal phylogenetically conserved do-
mains suspected to participate in SRAP functions. When analyzing
the effect of recruiting these domains, we found that the C-termi-
nal domain had by itself an inhibitory effect similar to the
full-length molecule (70–80% inhibition) whereas the N-terminal
region, also acting as a repressor, had a weaker impact (40% inhibi-
tion). Treatment with TSA (an inhibitor of HDAC activity) fully
abolished the repressive activity of the N-terminal domain (0%
inhibition of VP16 activity at 100 ng/mL TSA) but only partially
inhibited the effect of the full-length protein or its C-terminal do-
main (40% inhibition). The differential impact of TSA treatments
on the respective repressive action of these domains underlines a
possible heterogeneity of the mechanisms involved. It indeed sug-
gests that while the N-terminal mechanism of action mainly in-
volves HDACs, the C-terminal conserved domain might recruit
additional inhibitory proteins insensitive to TSA treatment. To fur-
ther investigate whether SRAP action might potentially involve the
recruitment of HDAC activity, we assessed HDAC activity in SRAP-
V5-tagged protein co-immunoprecipitated nuclear extracts from
previously described breast cancer cells (MCF-7-SRAP-V5-High.A)
stably expressing this protein (Fig. 3A). As control of non-speciﬁ-
cally immunoprecipitated HDAC activity we treated in parallel ex-
tracts from non-expressing cells (MCF-7-SE). We found that 0.2% of
total nuclear HDAC activity speciﬁcally co-immunoprecipitated
with SRAP-V5. To conﬁrm that endogenous SRAP could also form
complexes with known molecules harboring HDAC activity, we
have performed co-immunoprecipitation experiments using un-Fig. 3. Speciﬁc co-immunoprecipitation of SRAP-V5 and HDAC activity. (A) Nuclear
extracts from MCF-7-SE (control) and MCF-7-SRAP-V5-High.A cells were immuno-
precipitated with anti-V5 antibodies and HDAC activity measured as detailed in
Section 2. MCF-7-SRAP-V5-High.A extract was also treated in parallel with
competitive V5 peptide. Standard errors (n = 4) and signiﬁcant (Student’s t-test,
P < 0.05) difference with MCF-7-SE (control) are indicated by bars and stars,
respectively. (B) Nuclear extract from MCF-7 cells were divided into two pools and
subsequently immunoprecipitated with rabbit polyclonal anti-SRAP antibodies
(SRAP) or with non-speciﬁc rabbit polyclonal antibodies (NS) as described in
Section 2. Immunoprecipitated fractions (IP) or supernatant (Sup) were checked by
Western blot using anti-SRAP and anti-HDAC-2 antibodies. Nuclear extracts (Input)
was used as positive control.transfected MCF-7 breast cancer cell line nuclear extracts. We
found that HDAC-2 was associated with endogenous SRAP in this
model (Fig. 3B).
The potential to act through both HDACs and non-HDAC depen-
dent mechanisms has been demonstrated for other transcription
repressors. For example, the short heterodimer partner (SHP) and
the ligand-dependent nuclear receptor co-repressor LcoR can act
through EID1 (EP300 interacting inhibitor of differentiation 1)
and CtBP (C-terminal binding protein), respectively [12,17]. The
identity of the non-HDAC proteins possibly involved in SRAP med-
iated transcription repression remains to be determined.
The present observation that SRAP has an intrinsic repressive
ability contrasts with previous results presenting SRAP as an acti-
vator of transcriptional activity [1,7,20,22]. It should however be
noted that transcriptional co-regulators are known to behave dif-
ferentially in different cellular and promoter contexts. For exam-
ple, SRA differentially activates estrogen receptor controlled
transcription of reporter genes driven by different estrogen recep-
tor elements [21]. Similarly, molecules such as the co-activator
independent of AF-2 function (CIA) or the zinc-ﬁnger gene involved
in apoptosis and cell-cycle control (ZAC1), have the ability to act
either as co-activator or co-repressor [18,29]. Further studies are
urgently needed to establish what are the exact effects of SRAP
on the transcription of speciﬁc genes controlled by a particular
transcription factor in a given context.
The binding of a given transcription factor on a speciﬁc pro-
moter results in the sequential recruitment of multiple co-regula-
tory molecules. Using ChIP-re-ChIP experiments, Metivier et al.
have elegantly illustrated the complexity of the dynamic events
that occur following the initial recruitment of the estrogen recep-
tor alpha on the promoter of the estrogen dependent pS2 gene
[26]. Similar experiments could be performed to characterize the
co-recruitment of the estrogen receptor and SRAP on a given estro-
gen regulated promoter region. The two faces of the products of the
SRA1 gene, a functional RNA and a protein, however make the
choice of speciﬁc targets to be analyzed potentially challenging. In-
deed, even though both SRA-RNA and SRAP are believed to regulate
estrogen receptor activity [1,7,21,23], silencing SRA1 gene does not
affect the induction of pS2 gene by estrogen [4]. More recently,
Foulds et al. even reported that knocking down the expression of
both RNA and protein only affected a very small subset of direct
estrogen receptor target genes in MCF-7 breast cancer cells [14].
This emphasizes the need to ﬁrst identify endogenous target genes
speciﬁcally regulated by SRAP in order to further establish the bio-
logical signiﬁcance of the binding on promoter sites of this protein,
alone or associated with speciﬁc transcription factors. This could
potentially be achieved through the use of speciﬁc models allowing
the distinction between SRA-RNA and SRAP respective functions.
Interestingly, Foulds’s study also demonstrated that even
though silencing SRA modiﬁed the expression of a common subset
of genes in Hela uterus and MCF-7 breast cancer cell lines, some
other genes were differentially affected in the two cell types [14].
This highlights cell type differences in SRA/SRAP potential func-
tions, potentially resulting from the different relative amount of
transcription factors and co-regulators interacting with these two
regulatory molecules. For a given gene, SRAP effects on transcrip-
tion might therefore be positive or negative potentially as a direct
result of the balance between multiple transcription factors pres-
ent in speciﬁc cell types.
SRA is a very peculiar example of a bi-faceted system consisting
of a functional RNA and its corresponding protein. Our results
show for the ﬁrst time that SRAP can physically interact with mul-
tiple transcription factors and is recruited by promoter regions.
Altogether our data suggest that SRAP, as its RNA, has the potential
to be involved in many critical pathways and putatively directly
participates to the regulation of gene expression. Interestingly both
2224 S. Chooniedass-Kothari et al. / FEBS Letters 584 (2010) 2218–2224SRA-RNA and protein might be implicated in similar signaling
pathways. Speciﬁc studies deciphering SRAP and SRA exact mech-
anisms of action in the context of particular transcription factors
are warranted. Identifying SRA/SRAP target genes is crucial for a
comprehensive understanding of the bi-faceted system repre-
sented by the products of this peculiar gene.
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